Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 1—January 2021
Research

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines

Shalom Ben-Shimol, Noga Givon-Lavi, Leore Kotler, Bart Adriaan van der Beek, David Greenberg, and Ron DaganComments to Author 
Author affiliations: Ben-Gurion University of the Negev, Beer Sheva, Israel (S. Ben-Shimol, N. Givon-Lavi, L. Kotler, B.A. van der Beek, D. Greenberg, R. Dagan); Soroka University Medical Center, Beer Sheva (S. Ben-Shimol, N. Givon-Lavi, L. Kotler, D. Greenberg)

Main Article

Table 1

Postvaccine dynamics of pneumococcal conjugate vaccines in pediatric populations, Israel, October 2009–June 2017*

Epi year Carriage in healthy children, n = 2,638
 Carriage in non-LRTI, n = 2,450
 Carriage in LRTI, n = 1,819
 Conjunctivitis, n = 477
 Otitis media, n = 756
 IPD, n = 949
VT13 VT20–13 NVT20 VT13 VT20–13 NVT20 VT13 VT20–13 NVT20 VT13 VT20–13 NVT20 VT13 VT20–13 NVT20 VT13 VT20–13 NVT20
2009–10 ND ND ND 53 15 32 59 12 29 51 20 30 66 14 19 75 10 15
2010–11 ND ND ND 39 20 42 46 15 39 37 22 41 64 14 22 69 19 12
2011–12 21 15 64 26 21 53 29 19 51 28 20 52 36 22 42 35 48 17
2012–13 15 25 61 19 20 60 22 22 56 21 13 66 22 19 59 17 50 33
2013–14 10 25 65 15 20 65 19 16 65 14 23 62 23 28 49 19 53 28
2014–15 12 24 65 14 23 63 15 16 69 24 31 46 23 35 42 13 50 37
2015–16 11 24 66 10 23 67 14 32 56 13 17 70 16 27 57 9 52 39
2016–17 10 25 66 13 22 65 9 33 58 5 20 75 13 40 48 12 51 37
PRR† NA‡
 0.27 (0.21–0.34) 1.24 (0.99–1.54) 1.71 (1.53–1.92) 0.22 (0.17–0.29) 2.28 (1.77–2.94) 1.66 (1.44–1.91) 0.18 (0.09–0.37) 0.90 (0.54–1.52) 2.09 (1.58–2.76) 0.22 (0.12–0.37) 2.24 (1.48–3.37) 2.71 (1.98–3.72) 0.14 (0.09–0.21) 3.38 (2.51–4.55) 3.00 (2.10–4.28)

*Values are percentage of total pneumococcal isolates except as indicated. Epi, epidemiological; IPD, invasive pneumococcal disease; LRTI, lower respiratory tract infection; ND, no data; NVT20, serotypes not included in PCV20; PRR, prevalence rate ratio; VT13, serotypes included in 13-valent conjugate pneumococcal vaccine (PCV13); VT20-13, additional 20-valent PCV (PCV20) serotypes, not included in PCV13.
†2015–2017 vs. 2009–11.
‡Data from 2009–2011 not available.

Main Article

Page created: November 19, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external